Eq Rx, Inc. EQRX
We take great care to ensure that the data presented and summarized in this overview for EQRx, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EQRX
View all-
Ah Equity Partners Bio Iii, L.L.C. Menlo Park, CA19.2MShares$0100.0% of portfolio
-
Ah Equity Partners Bio Ii, L.L.C. Menlo Park, CA17.4MShares$060.15% of portfolio
-
Arboretum Ventures, Inc.13.9MShares$063.96% of portfolio
-
Ah Equity Partners Lsv I, L.L.C. Menlo Park, CA11.4MShares$08.42% of portfolio
-
Ah Equity Partners Lsv Ii, L.L.C. Menlo Park, CA5MShares$011.61% of portfolio
-
Beaumont Financial Partners, LLC731KShares$00.35% of portfolio
-
Pictet Asset Management Sa Geneva 73, V826.6KShares$00.0% of portfolio
Latest Institutional Activity in EQRX
Top Purchases
Top Sells
About EQRX
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at EQRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 09
2023
|
Eli Casdin > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
48,187,042
-100.0%
|
-
|
|
Nov 09
2023
|
Melanie Nallicheri Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,851,147
-100.0%
|
-
|
|
Nov 09
2023
|
Melanie Nallicheri Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,306,246
-100.0%
|
-
|
|
Nov 09
2023
|
Melanie Nallicheri Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
626,999
+9.04%
|
$1,253,998
$2.21 P/Share
|
|
Nov 09
2023
|
Paul L Berns Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
627,000
-100.0%
|
-
|
|
Nov 09
2023
|
Jorge Conde Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
53,064,157
-100.0%
|
-
|
|
Nov 09
2023
|
Dina Ciarimboli General Counsel and Secretary |
SELL
Sale (or disposition) back to the issuer
|
Direct |
731,750
-100.0%
|
-
|
|
Nov 09
2023
|
Sandra Horning Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
470,250
-100.0%
|
-
|
|
Nov 09
2023
|
Alexis Borisy Executive Chairman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,810,000
-100.0%
|
-
|
|
Nov 09
2023
|
Ah Equity Partners Bio Ii, L.L.C. > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
53,076,421
-100.0%
|
-
|
|
Nov 09
2023
|
Ah Equity Partners Lsv I, L.L.C. > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
53,076,421
-100.0%
|
-
|
|
Nov 09
2023
|
Amy Abernethy Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
200,000
-100.0%
|
-
|
|
Jul 01
2023
|
Dina Ciarimboli General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
575,000
+44.0%
|
-
|
|
Dec 17
2021
|
Paul L Berns Director |
BUY
Grant, award, or other acquisition
|
Direct |
627,000
+50.0%
|
-
|
|
Dec 17
2021
|
Alexis Borisy Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
18,810,000
+50.0%
|
-
|
|
Dec 17
2021
|
Amy Abernethy Director |
BUY
Other acquisition or disposition
|
Direct |
200,000
+50.0%
|
-
|
|
Dec 17
2021
|
Amy Abernethy Director |
SELL
Other acquisition or disposition
|
Direct |
200,000
-100.0%
|
-
|
|
Dec 17
2021
|
Amy Abernethy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
200,000
+50.0%
|
-
|
|
Dec 17
2021
|
Sandra Horning Director |
BUY
Grant, award, or other acquisition
|
Direct |
470,250
+50.0%
|
-
|
|
Dec 17
2021
|
Melanie Nallicheri Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
3,851,147
+50.0%
|
-
|